

Biomedical Research Progress International Conference

生物医药研究进展国际会议

July 5, 2018

Time 时间	Speakers 主讲人	University/Company 工作单位	Titles 报告题目
8:30-8:40	Welcome address by Dr. Youming Zhang 张友明教授致欢迎词		
Section 1: Chaired by Dr. Youming Zhang 第一场：主持人 张友明			
8:40-9:10	Dr. Jiang He 何江教授	Tulane University 美国杜兰大学	Sodium-sensitivity, sodium-resistance, and risk of hypertension 钠敏感性, 钠抗性和高血压风险
9:10-9:40	Dr. Yiping Yang 杨一平教授	Duke University Medical Center 美国杜克大学医学中心	Current Status and Challenges of Tumor CAR-T Therapy 肿瘤CAR-T治疗的现状与挑战
9:40-10:00	Photos and Coffee break 合影、茶歇		
Section 2: Chaired by Dr. Zihai Li 第二场：主持人 李子海			
10:00-10:30	Dr. Fengyi Liang 梁凤义教授	National University of Singapore 新加坡国立大学	ERM proteins, actin cytoskeleton and neuron-supporting cells of the nervous system ERM蛋白, actin细胞骨架与神经网络的支持细胞
10:30-11:00	Dr. Yadong Huang 黄亚东教授	University of California at San Francisco 美国加州大学旧金山分校	Precision Medicine and Drug Repurposing for Alzheimer's Disease 阿尔茨海默氏病的精准医疗和药物再利用
11:00-11:30	Dr. Yongjian Liu 刘永坚教授	Nanjing Medical University 南京医科大学	How the mechanistic study leads to next breakthrough of big drug in Parkinson's disease? 帕金森病的基础研究与药物研制的突破
11:30-12:00	Dr. Ruliang Xu 徐如良教授	New York University 美国纽约大学	Application of Precision Medicine 精准医学的应用
12:00-14:00	Lunch 午餐		

Section 3: Chaired by Dr. Yongjian Liu

第三场：主持人 刘永坚

14:00-14:30	Dr. Youming Zhang 张友明教授	Shandong University 山东大学	Red/ET DNA recombineering technology and its application Red/ET DNA重组技术及应用
14:30-15:00	Dr. Zihai Li 李子海教授	Medical University of South Carolina 美国南卡医科大学	Targeting Platelets and TGFbeta for Cancer Immunotherapy: Hype or Hope? 抗血小板和TGFbeta对癌症的免疫治疗：幻想还是希望？
15:00-15:30	Dr. Ke Zhang 张克教授	University of California at Los Angeles 美国加州大学洛杉矶分校	Novel allergy therapy through low affinity targeting of surface IgE 低亲和力抗IgE抗体介导的新型过敏疗法
15:30-16:00	Dr. Chengjiang Gao 高成江教授	Shandong University 山东大学	Regulation of innate immune signaling 天然免疫信号转导的调控机制
16:00-16:10	Coffee break 茶歇		

Section 4: Chaired by Dr. Ruliang Xu

第四场：主持人 徐如良

16:10-16:40	Dr. Zhenmin Ni 倪振民教授	Akrigene Diagnostics Inc 美国Akrigene Diagnostics公司	Research progress and clinical application of tumor exosomes 肿瘤外泌体研究进展和临床应用
16:40-17:10	Dr. Qingmei Jia 贾庆梅教授	University of California at Los Angeles 美国加州大学洛杉矶分校	Single vector platform vaccine protects against respiratory challenge with agents of anthrax, plague, tularemia, and tuberculosis 单载体疫苗预防多种致死性呼吸道感染性疾病的研究
17:10-17:40	Dr. Suhe Wang 王苏河教授	University of Michigan 美国密歇根大学	Development of an anti-microbial nanoemulsion for multi-drug resistant wound infections 纳米乳剂治疗多种耐药菌伤口感染的研究
17:40-18:10	Dr. Xiang Gao 高翔教授	Shandong University 山东大学	Typhoid Toxin: Molecular Mechanism of Unique Human Virulence and Therapeutic Possibilities 伤寒毒素：致病与治病
18:10-20:00	Dinner 晚宴		



Jiang He, MD, PhD, is Professor and Joseph S. Copes Chair of Epidemiology and Director of Translational Sciences Institute at Tulane University. Dr. He is a nationally and internationally well-known expert in the clinical, translational, and epidemiological research of cardiovascular and kidney diseases. He has conducted novel studies in obesity, hypertension, diabetes, stroke, cardiovascular disease, and chronic kidney disease funded by the National Institutes of Health. He has been the principal investigator and co-investigator for more than 30 major research awards from the National Institutes of Health worth more than 150 million US dollars. Dr. He has authored over 450 scientific articles and has published in first class biomedical journals, including New England Journal of Medicine, Journal of The American Medical Association, Lancet, and National Genetics. He has received many awards from local, national, and international academic institutions and professional societies.

何江医学博士是美国杜兰大学医学中心教授，杜兰大学公共卫生与热带医学学院流行病学系主任。何博士是国内和国际知名的心血管和肾脏疾病临床、转化和流行病学研究专家。他在美国国立卫生研究院资助的肥胖、高血压、糖尿病、中风、心血管疾病和慢性肾脏疾病方面进行了创新研究。他一直是美国国立卫生研究院 30 多项主要研究项目的主要研究者或共同研究者，研究项目价值超过 1.5 亿美元。何博士撰写了 450 多篇科学论文，并发表在一流的生物医学杂志上，包括新英格兰医学杂志，美国医学协会杂志，柳叶刀和国家遗传学杂志。他获得了许多地方、国家和国际学术机构和专业协会的奖项。



Yiping Yang, MD, PhD, Professor of Medicine and Immunology, Duke University Medical Center. Co-Director of Hematologic Malignancies and Cellular Therapy, Duke Cancer Institute. He has also served as Associate Editor for Journal of Clinical Investigation (JCI) and JCI Insight.

Dr. Yang received his M.D. from Zhejiang University, and Ph.D. from University of Michigan. He then completed his postdoctoral training and Internal Medicine residency at the University of Pennsylvania, and his Medical Oncology fellowship at Johns Hopkins University. He is an ABIM-certified physician with clinical interest in lymphoma and leukemia. He has been selected as America's top oncologist since 2008. Funded by grants from National Institute of Health and private foundations, his research focuses on cancer immunology and immunotherapy, as well as gene therapy and viral immunity. He has published more than 100 peer-reviewed papers in journals including Science, Nature Immunology, Nature Genetics, Nature Medicine, Immunity, JCI, PNAS, etc.

杨一平

医学博士，细胞分子生物学博士

美国杜克大学（Duke University）医学、免疫学终身教授

杜克大学肿瘤院血液恶性肿瘤和细胞治疗中心主任


美国内科协会认可的血液肿瘤专家，连续多年当选美国顶尖肿瘤学家，并兼任国际权威医学杂志 JCI, JCI Insight 编委和副主编。美国国家卫生院（NIH）等基金评定委员会成员及 Science, Nature, Nature Immunology, Immunity, JCI, PNAS 等高影响力国际学术期刊审稿人。主要从事基因治疗，病毒免疫，肿瘤免疫及细胞治疗的研究，获多项医学研究成果及专利权，并先后在 Science, Nature Medicine, Nature Immunology, Nature Genetics, Immunity, JCI, PNAS, Blood 等国际权威杂志上发表论文一百余篇。主持参与 NIH 等数十项基金项目，并在肿瘤免疫和细胞治疗的基础研究和临床应用方面取得卓越的成就。



Fengyi Liang, MD, PhD, is associate professor in department of Anatomy, Yong Loo Lin School of Medicine, National University of Singapore. Dr. Liang received a doctorate from the Institute of Physiology, University of Fribourg, Switzerland in 1993. Then engaged in postdoctoral work in Department of Anatomy and Neurobiology, University of California, Irvine. From 1996, Dr. Liang began working as staff scientist in Brain Science Institute, Institute of Phys & Chem Res (RIKEN), Japan. Since 2001, Dr. Liang has served at the Department of Anatomy, Yong Loo Lin School of Medicine, National

University of Singapore and was promoted to associate professor in 2008. The research interests of Dr. Liang include Neurobiology, neural plasticity, neuroglia & mechanisms of neurological/psychiatric diseases; Synaptic plasticity and identification/characterization of related genes/proteins; Gene polymorphism/mutations in neurological/psychiatric diseases and brain ageing; Neuroglia & cytoskeleton-related oligodendroglial proteins.

梁凤仪医学博士现任新加坡国立大学 Yong Loo Lin 医学院解剖学系副教授。1993 年获得瑞士弗里堡大学博士学位，然后在美国加州大学尔湾分校解剖与神经生物学系从事博士后工作，1996 年开始在日本物理化学研究所 (RIKEN) 脑科学所担任专职科学家。2001 年至今在新加坡国立大学任职，2008 年晋升为副教授。梁博士研究方向包括神经生物学，神经可塑性，神经胶质和神经/精神疾病的机制，突触可塑性和相关基因/蛋白质的鉴定，基因多态性/神经/精神疾病和脑老化的突变，神经胶质细胞和细胞骨架相关的少突神经胶质蛋白。



Yadong Huang, M.D., Ph.D.

Director, Gladstone Center for Translational Advancement

Senior Investigator, Gladstone Institute of Neurological Disease

Professor of Neurology and Pathology

University of California, San Francisco, USA

Dr. Huang has been studying the mechanism of memory formation and the pathogenesis of Alzheimer's disease using transgenic and gene-targeted mouse models, mouse primary neurons, and human neurons derived from induced pluripotent stem cells (iPSCs). He currently leads eight Alzheimer's disease research and drug development programs funded by National Institutes of Health, USA, with total funding over \$25,000,000. Dr. Huang has published more than 120 peer-reviewed scientific papers in journals including *Cell*, *Cell Stem Cell*, *Nature Medicine*, *Neuron*, and *PNAS*. He has also been heavily involved in developing strategies for treating Alzheimer's disease, and is an inventor on 11 patents. He is a co-founder and scientific advisory board chair of two pharmaceutical companies, E-Scape Bio, Inc. and GABAeron, Inc.

黄亚东

医学博士，细胞生物学博士

Gladstone 转化医学中心主任

Gladstone 神经疾病研究所资深研究员

美国加州大学旧金山分校神经及病理学教授

黄亚东博士从事正常记忆形成及老年痴呆症发病机理的研究二十余年。目前主持八项美国国立卫生研究院资助的科研项目，总资金超过二千五百万美元。先后在 *Cell*, *Cell Stem Cell*, *Nature Medicine*, *Neuron*, *PNAS* 等国际权威杂志上发表论文一百二十余篇，并获多项医学研究成果及十一项专利权。黄亚东博士还在美国创办了 E-Scape Bio, Inc. 和 GABAeron, Inc. 两家生物医药公司，并担任科学顾问委员会主席。



Liu Yongjian, Professor of Nanjing Medical University, Visiting Associate Professor of the University of Pittsburgh School of Medicine. Professor Liu's research experience in the United States and independent PI in the past more than 20 years has long focused on the basic theoretical exploration of molecular cell biology and its role in the pathogenesis of Parkinson's disease (PD). During the postdoctoral work of UCLA, the molecule cloned the first family of vesicular neurotransmitter transporters (VMATs) that endogenously protect dopaminergic neurons. The article was published in the

famous journal Cell, PNAS, "JCB" etc.; Professor Liu has served as an assistant professor at UCSF and Pittsburgh for more than ten years, incorporating the concept of cell membrane transport into neurotransmitter delivery and neuronal specific organelles such as synaptic vesicle formation and functional studies. At the same time, Prof. Liu also has achievements in scientific research, such as discovering the new mTOR regulation mechanism and publishing it in "Science". His laboratory work has long been supported by NIH's R01, R21, and the National Natural Science Foundation of China, recent studies on molecular regulation of subcellular membrane trafficking and molecular pathogenesis of PD pathogenicity genes such as LRRK2 in the pathogenesis of PD. Theoretical advances have been made in the study of biological mechanisms and clinical applications.

刘永坚，南京医科大学教授，美国匹兹堡大学医学院客座副教授。刘教授近20多年来在美国学习和独立PI的研究经历中，长期专注于在分子细胞生物学基本理论探索及在帕金森氏病（PD）的发病机制中的作用。在UCLA的博士后工作期间，分子克隆了第一个具有对多巴胺能神经元起内源性保护作用的囊泡神经递质转运蛋白家族（VMATs），文章发表在著名杂志“细胞”，“PNAS”，“JCB”等；刘教授在UCSF及匹兹堡任助理教授十多年间，将细胞膜运输的概念融入神经递质传递和神经特异性亚细胞器如突触囊泡等的形成和功能研究。同时，刘教授亦有科研合作成果如发现新的mTOR的调节机制并在“科学”上发表。他的实验室的工作长期得到美国NIH的R01，R21，以及中国国家自然科学基金的资助，近期对亚细胞逆膜运输的分子调节机制研究以及PD致病基因LRRK2等在PD发病中的分子细胞生物学机制研究和临床应用方面取得了理论性进展。



Ruliang Xu, MD, PhD. Dr. Ruliang Xu is a professor of pathology, director of Gastrointestinal and Liver Pathology Service, and director of GI and Liver Pathology Fellowship training program, former director of Molecular Diagnostic Pathology Laboratory at New York University Langone Medical Center/ School of Medicine. He serves editorial board member in multiple international journals of gastrointestinal and liver pathology.

As an academic pathologist, he has been leading and participating in many research projects on carcinogenesis in the gastrointestinal tract, pancreas, and liver. He has published many original research articles, reviews, and book chapters in reputable journals, and was invited to speak at many national and international meetings.

徐如良医师博士现任美国纽约大学医学中心病理系教授，胃肠和肝胆病理主任，胃肠和肝胆病理专科医师训练部主任，前分子诊断实验室主任，多家国际性病理和肝病杂志编委。

徐医师领导和参与了多个胃肠道，胰腺和肝脏癌变的研究项目。他在著名期刊发表了许多原创性研究文章，评论和书籍章节，并多次应邀在国内和国际会议上作学术报告。



Youming Zhang, M.D., Ph.D. Professor and Dean of the Institute of Microbial Technology, Shandong University, Director of the State Key Laboratory of Microbial Technology, and the winner of the National Tenth Batch of Innovative “Thousand Talents Program”. Dr. Zhang received his Ph.D. from the University of Heidelberg, Germany in 1994. During 1998-2000, as a senior researcher at the European Molecular Biology Laboratory, he invented Red/ET technology. Red/ET recombination engineering and direct cloning technology is a milestone in the field of genetic engineering. It is an essential technique for genetic

modification of DNA macromolecules. This technology is used by more than 500 scientific research institutions and most large biotech companies and pharmaceutical companies in the world. Dr. Zhang joined Shandong University in April 2013. After living in Germany for 23 years, he returned to China with a technical team. Now his research interests include development research on DNA engineering technology based on Red/ET recombineering, direct clone and heterologous expression of gene clusters of natural products, direct clone and heterologous expression of magnetosomes gene cluster and the application in anti-cancer target drugs. Dr. Zhang has published more than 90 peer-reviewed papers in journals such as Nature, Nature Genetics, Nature Biotechnology, Nature Nanotechnology, PNAS. The total IF is greater than 550, the total citations more than 9230, H-index 43, with 13 international patents.

张友明，山东大学教授，山东大学微生物技术研究院院长，微生物技术国家重点实验室主任，国家第10批创新“千人计划”获得者。1994年获德国海德堡大学医学院博士学位，1998-2000年在任欧洲分子生物学实验室高级研究员期间发明Red/ET技术。Red/ET重组工程和直接克隆技术是基因工程领域的一个里程碑，是DNA大分子遗传修饰的必备技术，世界上有超过500个科研机构和大公司的生物技术大公司和医药公司都在使用该技术。2013年4月被山东大学引进，留德23年后带着技术团队回国。他目前的研究方向包括以Red/ET重组工程技术为主的DNA操作技术开发，微生物天然产物基因簇的直接克隆和异源表达，磁小体基因簇的直接克隆及肿瘤靶向治疗应用技术。发表SCI文章90余篇，总影响因子大于550，总引用指数大于9230，H-index 43，国际专利13项。学术成果在Nature，Nature Genetics, Nature Biotechnology, Nature Nanotechnology, PNAS等杂志上发表。



Zihai Li, M.D., Ph.D. A physician scientist and elected member of the American Society of Clinical Investigation (ASCI) and American Association of Physicians (AAP), Dr. Zihai Li is now professor and chair of Department of Microbiology and Immunology, endowed chair in stem cell biology and the co-leader of the Cancer Immunology program at the National Cancer Institute (NCI)-designated Hollings Cancer Center at the Medical University of South Carolina (MUSC) in Charleston, South Carolina, USA.

As a board-certified medical oncologist and basic science department chair, Dr. Zihai Li plays unique roles in advancing academic missions at multiple levels. His research interests in the last 20-plus years have been primarily in the field of chaperone biology, immune tolerance, and cancer immunology, particularly related to the roles of a key immune chaperone gp96 in the endoplasmic reticulum. Dr. Li's laboratory focuses currently on developing better cancer immunotherapeutics via reprogramming the tolerogenic tumor microenvironment. Dr. Li has published 130-plus peer-reviewed manuscripts on the topics of tumor immunology, immune tolerance, and chaperone biology in journals such as EMBO J, J Exp Med, Immunity, Blood, J Clin Invest, J Biol Chem, Nat Med, J Immunol, Sci Immunol, Nat Struct Mol Biol and Nat Commun.

李子海博士，美国临床研究协会（ASCI）和美国资深医生科学家协会（AAP）成员，南卡罗来纳医科大学（MUSC）教授，微生物学和免疫学系主任，美国国家癌症研究所（NCI）癌症免疫学项目共同负责人。

作为美国内科协会认可的医学肿瘤学专家和基础医学科学系主席，李子海博士在推进多层次学术任务方面发挥独特作用。在过去 20 多年的研究内容主要集中在分子伴侣生物学，免疫耐受和癌症免疫学领域，特别是与内质网中关键免疫伴侣 gp96 的作用。李博士的实验室目前致力于通过改变耐受性肿瘤微环境来开发更好的癌症免疫治疗药物。他发表了 130 多篇同行评议论文，内容涉及肿瘤免疫学，免疫耐受和分子伴侣生物学，期刊如 EMBO J, J Exp Med, Immunity, Blood, J Clin Invest, J Biol Chem, Nat Med, J Immunol, Sci Immunol, Nat Struct Mol Biol 和 Nat Commun 等。



Ke Zhang, MD, PhD,
Dr. Zhang is a co-founder and Chief Scientific Officer at Sixal Inc. He also is a Professor of Medicine in Clinical Immunology and Allergy in David Geffen School of Medicine at UCLA. Dr. Zhang's research interest focused on 1). Mechanism of allergy and development of novel allergy therapy; 2). Human antibody isotype switching and Ig somatic hypermutation.

张克，医学博士。美国加州大学洛杉矶分校医学院过敏反应及临床免疫学教授，Sixal 公司联合创始人兼首席科学家。研究方向：过敏反应机制及抗过敏新药研发，抗体多样性机理。



Chengjiang Gao, PhD

Professor of Immunology, Shandong University the Basic Biomedical Sciences, vice dean of the School of Biomedical Sciences of Shandong University, director of the Key Laboratory of Infection and Immunity of Shandong Province. Dr. Gao received his BS degree from the department of Biology of Shandong University in 1995, and his PhD degree from Shanghai Institute of Plant Physiology, Chinese Academy of Sciences in 2000. He trained as a postdoctoral fellow from 2001 to 2007 at University of California at Davis and Duke University School of Medicine, respectively.

In 2007, Dr. Gao returned to China and was promoted to full professor of Shandong University.

The main research of Prof. Gao is to explore how the activation of innate immunity is regulated after virus infection. During the past ten years, he focused on the protein ubiquitination in the regulation of innate immunity. His lab has identified several ubiquitin E3 ligases and deubiquitinating enzymes to regulate the innate antiviral immune signaling by targeting various molecules in innate antiviral immunity. He has published more than 20 papers in international journals such as Nature Immunology, Journal of Experimental Medicine, Nature Communications, PLOS Pathogen and Journal of Immunology. He was elected as the distinguished professor for both Taishan scholar of Shandong Province and Yangtze River scholar of Ministry of Education in 2007 and 2017 respectively. Moreover, he is the winner of the National Science Fund for Distinguished Young Scholars in 2015.

高成江，山东大学免疫学教授，长江学者，国家杰青，泰山学者。

1995年于山东大学生物系获得学士学位，2000年于中国科学院上海植物生理研究所获得博士学位。2001-2007年分别赴美国加州大学戴维斯分校和杜克大学做博士后研究，2007年被选聘为山东省泰山学者特聘教授，回到山东大学医学院工作，任教授、博士生导师。现任山东大学基础医学院副院长、山东省感染与免疫学重点实验室主任。主要从事天然免疫信号转导的调控机制研究，以病毒感染为模型，系统探索天然免疫信号转导以及炎症反应的调控机制，发现了多个调控抗病毒天然免疫信号转导的泛素化修饰酶，研究成果发表在 Nat Immunol、J Exp Med、Nat Commun、PLOS Pathog 等国际知名杂志。分别于 2007 年和 2017 年被选聘为山东省泰山学者和教育部长江学者特聘教授，2015 年获得国家杰出青年基金资助。



Zhenmin Ni, graduated from Lanzhou University Medical School and Peking Union Medical College. After graduation, he had been teaching at Beijing Union Medical College, University of Southern California and the University of California, Irvine. He is engaged in subjects such as anti-oxidation and anti-inflammation therapy in renal diseases and hypertension; individualized nutrition and health assessment and program design; and cancer

diagnosis. He has published more than 60 research papers on "Hypertension"、"Kidney International", and so on. His research results have been incorporated in "Massry & Glassock's Nephrology Textbook". He has won the Shaul Massry Research Foundation Award from the American Nephrology Association. After 2012, He focus on high-tech investment and financing. Currently holds the president and CEO of Akrigene Diagnostics of the United States. He also participated in the founding of Alljoy Health Plus (former CTO), Personal Health Designer (Chief Scientist), Orange Bigdata LLC (Founding Partner), Frost Big Data Incubator (Investor), and he serves as advisors in some incubators, associations and corporate ventures.

倪振民，医学博士，毕业于中国兰州大学医学院和北京协和医科大学/中国医学科学院。毕业后在北京协和医学院、南加州大学和加州大学尔湾分校任教。从事肾脏病、高血压、营养基因组学 (nutrigenomics)、抗氧化、抗炎、肿瘤检测诊断及个体化健康营养评估和方案设计等学科研究。在《高血压》、《国际肾脏病》等上发表研究论文六十余篇，成果收入《Massry & Glassock's 肾脏病学教科书》，获美国肾脏病学会 Shaul Massry 研究基金奖。

2012年后专注高科技投融资。目前担任美国 Akrigene Diagnostics 董事长兼 CEO。还曾参与创办 Alljoy Health Plus (前 CTO)、Personal Health Designer (首席科学家)、Orange Bigdata LLC (创始合伙人)、Frost 大数据孵化器 (投资人) 等企业，并在一些孵化器或企业兼职科技创投顾问。



Qingmei Jia, PhD

Dr. Jia received her Ph.D. in Microbiology, Immunology and Pathology from the University of Tokyo, Japan. She is currently a Researcher of Infectious Diseases at the UCLA David Geffen School of Medicine. Dr. Jia focus on studies of poliovirus neuro - tropism and vaccine development. Dr. Jia has been leading projects in studies of molecular pathogenesis and vaccine development for AIDS - related tumor viruses (gammaherpesvirus) and infectious diseases. She pioneered the application of RNA interference (RNAi) technique on studies of gammaherpesvirus molecular pathogenesis. During recent years, she has been focusing on the development of novel vaccines against infectious diseases, including tuberculosis, one of the deadliest diseases in the world, and Tier I Select Agents (tularemia, plague and anthrax), i.e. the most likely pathogens to be deliberately used in a bioterrorist attack. Her studies have been continuously funded by Japan and US agencies; her achievements on vaccine development have resulted in multiple patents filed in Japan and US; her studies have been presented in numerous international conferences and resulted in more than 30 peer - reviewed original and review articles in international scientific journals. She has also served as reviewers for multiple scientific journals.

贾庆梅,日本东京大学病理、免疫与微生物学博士; 现任美国加州大学洛杉矶分校大卫格芬医学院传染病学 (UCLA David Geffen School of Medicine) 研究员。2001 年至今在 UCLA 从事艾滋病相关肿瘤病毒 (gammaherpesvirus) 的分子病理机制以及肿瘤和传染病疫苗的研究工作。她首次将 RNA 干扰 (RNAi) 的技术用于 gammaherpesvirus 分子病理机制的研究。近年来, 她专注于抗结核, 兔热病, 鼠疫, 和炭疽病等的新型疫苗的研究与开发。其研究项目持续多年获得日本和美国各种基金的资助; 其研究成果获日本, 美国和国际专利数项, 在国际学术会议发表 20 多次, 在专业杂志 (Journal of Virology, Infection and Immunity, Vaccine, Journal of Immunology, Journal of Structural Biology, Scientific Reports 等) 发表论文 30 多篇; 她还参与数个专业杂志的审稿工作。



Suhe Wang, M.D., Ph.D.

Dr. Wang graduated from the University of Strathclyde, UK and received a Ph.D. in Pharmacy in 1996. She is currently an associate professor at the Institute of Nanotechnology, Medical and Biological Sciences, University of Michigan Medical School. The main research directions are: Cell, molecular biology and nanomedicine, especially new nanomaterials/emulsions for anti-infection, vaccine adjuvants, molecular targeted drugs, nano-anticancer materials and autoimmune regulators. The above studies

were funded by different funds, including the United States DOD, the United States NIH and the United States Thyroid Research Committee.

Currently, one of her major research topics is the application of new nanoemulsions for the treatment of antibiotic-resistant infections. The ultimate goal of the study is to develop this nanoemulsion into a new clinical and practical anti-infection emulsion that can kill a variety of antibiotic-resistant pathogens. He has published more than 60 research papers in related professional journals, compiled six book chapters, obtained several US patents, and has been involved in the review of many professional magazines and fund review.

王苏河, 1996年毕业于英国斯特拉思克莱德大学并获得药学博士学位。现任美国密歇根大学医学院, 医学和生物科学纳米技术研究所副教授。研究的主要方向为: 细胞、分子生物学和纳米医学, 尤其是抗感染的新型纳米材料/乳剂, 疫苗佐剂, 分子靶向药物, 纳米抗癌材料和自身免疫调节剂的研究开发。以上的研究得到不同基金的资助, 包括美国 DOD, 美国 NIH 和美国甲状腺研究委员会。

目前, 她的主要研究课题之一是应用新型纳米乳剂治疗对抗生素抵抗的感染, 该研究的最终目标是将此纳米乳剂发展为可杀伤对多种抗生素抵抗病原菌的新临床实用型抗感染乳剂。在相关的专业期刊上发表科研论文 60 多篇, 编写 6 本书籍章节, 获得美国专利数项, 并一直参与多个专业杂志审稿和基金评审。



Xiang Gao, Ph.D. Professor of the Institute of Microbial Technology, Shandong University, and awardee of “One Thousand Young Talents Plan.” Dr. Gao got his Ph.D. from Tsinghua University in 2012. Then he moved to the Yale School of Medicine for his postdoctoral training. His research has mainly focused on the mechanisms of microbial pathogenesis with the overall goal of generating new ideas for developing novel strategies to combat microbial infections. He has published several peer-reviewed papers in the scientific journals as the first or co-first author, including Nature, Science, Cell, Cell Host & Microbe and Nature

Microbiology. He also got some very high competitive awards, including Ray Wu Prize, James Hudson Brown - Alexander B. Coxef fellowship and Blavatnik Regional Award. His studies on typhoid toxin revealed unique insights into several aspects of the unique biology of this toxin including its assembly, its receptor binding specificity, its role in typhoid fever pathogenesis and the remarkable evolutionary path that produced this highly unusual toxin, which opens up unique avenues for the development of both effective vaccines as well as therapeutic strategies to treat patients that have contracted the Typhoid Fever. In 2017, he moved back to China and joined in the Institute of Microbial Technology, Shandong University. In his lab, they aim to understand the mechanisms of interaction between the microbiota, pathogens and the host within the human gut through combining multiple approaches.

高翔 山东大学微生物技术研究院教授，国家“青年千人计划”入选者。2012年获得清华大学博士学位，随后在耶鲁大学医学院进行博士后训练。对肠道病原微生物与宿主的相互作用及其致病的分子机制进行研究。以第一作者身份在 Nature、Science、Cell、Cell Host & Microbe 以及 Nature Microbiology 等杂志上发表科学研究论文多篇。获 Ray Wu Prize, James Hudson Brown - Alexander B. Coxef fellowship 和 Blavatnik Regional Award 等奖励。关于人伤寒沙门氏菌致病因子——伤寒毒素的研究工作揭示了人伤寒沙门氏菌宿主特异性的分子机制以及人伤寒沙门氏菌与宿主共进化的分子机制，为开发新型伤寒疫苗以及治疗伤寒提供了新的思路。2017年加入山东大学微生物技术研究院，开展肠道微生物与宿主相互交流、相互作用分子机制的研究。